summary: Interferon beta is an accepted treatment for relapsing-remitting MS. It has been suggested that the earlier the IFN is given, the greater the benefit, although this view is controversial. This is a descriptive study where more than 2,500 people with MS treated with interferon beta have been followed for between seven to 15 years. The authors found that a reduced disability progression was observed for people who started IFN treatment within the first year after the onset of the disease.

authors: Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group

source: Ann Neurol. 2009 May 28;66(4):513-520

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: